{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:40:17Z","timestamp":1792885217674,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00210-026-05573-6","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:26:18Z","timestamp":1782433578000},"page":"19597-19616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safranal improves the anticancer efficacy of sorafenib via transcriptomic reprogramming and metabolomic changes in a rat model of diethylnitrosamine-induced cirrhosis\u2013hepatocellular carcinoma"],"prefix":"10.1007","volume":"399","author":[{"given":"Ameera","family":"Al Mansoori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badriya","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Harati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Sami","family":"Alhamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin A.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Al-Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Hamoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"5573_CR1","doi-asserted-by":"publisher","unstructured":"Abdalla A, Murali C, Amin A (2022a) Safranal inhibits angiogenesis via targeting HIF-1\u03b1\/VEGF machinery: in vitro and ex vivo insights. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.789172","DOI":"10.3389\/fonc.2021.789172"},{"key":"5573_CR2","doi-asserted-by":"publisher","unstructured":"Abdalla Y, Abdalla A, Hamza AA, Amin A (2022b) Safranal prevents liver cancer through inhibiting oxidative stress and alleviating inflammation. Front Pharmacol\u00a012. https:\/\/doi.org\/10.3389\/fphar.2021.777500","DOI":"10.3389\/fphar.2021.777500"},{"issue":"6","key":"5573_CR3","doi-asserted-by":"publisher","first-page":"101042831769912","DOI":"10.1177\/1010428317699127","volume":"39","author":"HA Aglan","year":"2017","unstructured":"Aglan HA, Ahmed HH, El-Toumy SA, Mahmoud NS (2017) Gallic acid against hepatocellular carcinoma: an integrated scheme of the potential mechanisms of action from in vivo study. Tumor Biol 39(6):101042831769912. https:\/\/doi.org\/10.1177\/1010428317699127","journal-title":"Tumor Biol"},{"issue":"2","key":"5573_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jneumeth.2008.05.003","volume":"172","author":"GM Aldridge","year":"2008","unstructured":"Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ (2008) The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods 172(2):250\u2013254. https:\/\/doi.org\/10.1016\/j.jneumeth.2008.05.003","journal-title":"J Neurosci Methods"},{"issue":"9","key":"5573_CR5","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.3390\/ijms26094194","volume":"26","author":"F Alhosani","year":"2025","unstructured":"Alhosani F, Alhamidi RS, Ilce BY, Altaie AM, Ali N, Hamad AM, K\u00fcnstner A, Khandanpour C, Busch H, Al-Ramadi B, Harati R, Sayed K, AlFazari A, Bendardaf R, Hamoudi R (2025) Transcriptome-wide analysis and experimental validation from FFPE tissue identifies stage-specific gene expression profiles differentiating adenoma, carcinoma in-situ and adenocarcinoma in colorectal cancer progression. Int J Mol Sci 26(9):4194. https:\/\/doi.org\/10.3390\/ijms26094194","journal-title":"Int J Mol Sci"},{"issue":"19","key":"5573_CR6","doi-asserted-by":"publisher","first-page":"10367","DOI":"10.3390\/ijms251910367","volume":"25","author":"F Alhosani","year":"2024","unstructured":"Alhosani F, Ilce BY, Alhamidi RS, Bhamidimarri PM, Hamad AM, Alkhayyal N, K\u00fcnstner A, Khandanpour C, Busch H, Al-Ramadi B, Sayed K, AlFazari A, Bendardaf R, Hamoudi R (2024) Transcriptome profiling associated with CARD11 overexpression in colorectal cancer implicates a potential role for tumor immune microenvironment and cancer pathways modulation via NF-\u03baB. Int J Mol Sci 25(19):10367. https:\/\/doi.org\/10.3390\/ijms251910367","journal-title":"Int J Mol Sci"},{"key":"5573_CR7","doi-asserted-by":"publisher","unstructured":"Al-Hrout A, Chaiboonchoe A, Khraiwesh B, Murali C, Baig B, El-Awady R, Tarazi H, Alzahmi A, Nelson DR, Greish YE, Ramadan W, Salehi-Ashtiani K, Amin A (2018). Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells. Sci Rep 8(1). https:\/\/doi.org\/10.1038\/s41598-018-34855-0","DOI":"10.1038\/s41598-018-34855-0"},{"key":"5573_CR8","unstructured":"Amin A, AlMansoori A, Baig B (2020) Safranal-sorafenib combination therapy for liver cancer. U.S. Patent No. US 10,568,873 B1. Assignee: United Arab Emirates University, Al Ain, UAE\u00a0"},{"issue":"3","key":"5573_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/hep.24433","volume":"54","author":"A Amin","year":"2011","unstructured":"Amin A, Hamza AA, Bajbouj K, Ashraf SS, Daoud S (2011) Saffron: a potential candidate for a novel anticancer drug against hepatocellular carcinoma. Hepatology 54(3):857\u2013867. https:\/\/doi.org\/10.1002\/hep.24433","journal-title":"Hepatology"},{"issue":"1","key":"5573_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1574892810666151102110248","volume":"11","author":"A Amin","year":"2016","unstructured":"Amin A, Hamza AA, Daoud S, Khazanehdari K, Al Hrout A, Baig B, Chaiboonchoe A, Adrian TE, Zaki N, Salehi-Ashtiani K (2016) Saffron-based crocin prevents early lesions of liver cancer: in vivo, in vitro and network analyses. Recent Pat Anti-Cancer Drug Discov 11(1):121\u2013133. https:\/\/doi.org\/10.2174\/1574892810666151102110248","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"issue":"13","key":"5573_CR11","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/molecules26133855","volume":"26","author":"A Amin","year":"2021","unstructured":"Amin A, Farrukh A, Murali C, Soleimani A, Praz F, Graziani G, Brim H, Ashktorab H (2021) Saffron and its major ingredients\u2019 effect on colon cancer cells with mismatch repair deficiency and microsatellite instability. Molecules 26(13):3855. https:\/\/doi.org\/10.3390\/molecules26133855","journal-title":"Molecules"},{"issue":"2","key":"5573_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W (2015) HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2):166\u2013169. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638","journal-title":"Bioinformatics"},{"issue":"16","key":"5573_CR13","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.3390\/cancers15164063","volume":"15","author":"B Awad","year":"2023","unstructured":"Awad B, Hamza AA, Al-Maktoum A, Al-Salam S, Amin A (2023) Combining crocin and sorafenib improves their tumor-inhibiting effects in a rat model of diethylnitrosamine-induced cirrhotic-hepatocellular carcinoma. Cancers 15(16):4063. https:\/\/doi.org\/10.3390\/cancers15164063","journal-title":"Cancers"},{"issue":"1","key":"5573_CR14","first-page":"27","volume":"16","author":"SZ Bathaie","year":"2013","unstructured":"Bathaie SZ, Miri H, Mohagheghi M-A, Mokhtari-Dizaji M, Shahbazfar A-A, Hasanzadeh H (2013) Saffron aqueous extract inhibits the chemically-induced gastric cancer progression in the Wistar albino rat. Iran J Basic Med Sci 16(1):27\u201338","journal-title":"Iran J Basic Med Sci"},{"issue":"50","key":"5573_CR15","doi-asserted-by":"publisher","first-page":"87684","DOI":"10.18632\/oncotarget.21196","volume":"8","author":"A Bort","year":"2017","unstructured":"Bort A, Sp\u00ednola E, Rodr\u00edguez-Henche N, D\u00edaz-Laviada I (2017) Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget 8(50):87684\u201387698. https:\/\/doi.org\/10.18632\/oncotarget.21196","journal-title":"Oncotarget"},{"issue":"4","key":"5573_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/labinvest.2010.205","volume":"91","author":"M Cao","year":"2011","unstructured":"Cao M, Xu Y, Youn J, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C (2011) Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest 91(4):598\u2013608. https:\/\/doi.org\/10.1038\/labinvest.2010.205","journal-title":"Lab Invest"},{"key":"5573_CR17","doi-asserted-by":"publisher","unstructured":"Chen S, Liu JP, Li X, Dang S, Li W (2025) Sorafenib with or without co-interventions for hepatocellular carcinoma. Cochrane Database of Syst Rev 2025(6). https:\/\/doi.org\/10.1002\/14651858.cd015851","DOI":"10.1002\/14651858.cd015851"},{"key":"5573_CR18","doi-asserted-by":"publisher","unstructured":"Cho S, Kim W, Yoo D, Han Y, Hwang H, Kim S, Kim J, Park S, Park Y, Jo H, Pyun J, Lee M (2024) Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells. Sci Rep 14(1). https:\/\/doi.org\/10.1038\/s41598-024-52160-x","DOI":"10.1038\/s41598-024-52160-x"},{"issue":"10","key":"5573_CR19","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1535-7163.mct-12-0093","volume":"11","author":"R Coriat","year":"2012","unstructured":"Coriat R, Nicco C, Ch\u00e9reau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F (2012) Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 11(10):2284\u20132293. https:\/\/doi.org\/10.1158\/1535-7163.mct-12-0093","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"5573_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","volume":"12","author":"SM Crusz","year":"2015","unstructured":"Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12(10):584\u2013596. https:\/\/doi.org\/10.1038\/nrclinonc.2015.105","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"5573_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.acthis.2009.02.003","volume":"112","author":"I Das","year":"2010","unstructured":"Das I, Das S, Saha T (2010) Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: a histopathological study. Acta Histochem 112(4):317\u2013327. https:\/\/doi.org\/10.1016\/j.acthis.2009.02.003","journal-title":"Acta Histochem"},{"issue":"8","key":"5573_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cncr.29912","volume":"122","author":"DK DePeralta","year":"2016","unstructured":"DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, Chung RT, Tanabe KK, Fuchs BC (2016) Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 122(8):1216\u20131227. https:\/\/doi.org\/10.1002\/cncr.29912","journal-title":"Cancer"},{"issue":"2","key":"5573_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10238-016-0416-3","volume":"17","author":"NE El-Ashmawy","year":"2017","unstructured":"El-Ashmawy NE, Khedr EG, El-Bahrawy HA, Abd El-Fattah EE (2017) Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med 17(2):185\u2013191. https:\/\/doi.org\/10.1007\/s10238-016-0416-3","journal-title":"Clin Exp Med"},{"key":"5573_CR24","doi-asserted-by":"publisher","unstructured":"Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, Neisser M, Nguyen C, Lee R, Park JK, Reyes J, Hartung T, Rojas C, Rais R, Tsukamoto T, Le A (2016) Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci USA 113(36). https:\/\/doi.org\/10.1073\/pnas.1611406113","DOI":"10.1073\/pnas.1611406113"},{"issue":"38","key":"5573_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0973-1296.133296","volume":"10","author":"J Farahzad","year":"2014","unstructured":"Farahzad J, Samarghandian S, Shoshtari M, Sargolzaei J, Hossinimoghadam H (2014) Anti-tumor activity of safranal against neuroblastoma cells. Pharmacogn Mag 10(38):419. https:\/\/doi.org\/10.4103\/0973-1296.133296","journal-title":"Pharmacogn Mag"},{"key":"5573_CR26","doi-asserted-by":"crossref","unstructured":"Fayed HM, Asaad GF, Elbaset MA, Sharaf OA, Mahmoud SS, Amin MM, El-Gendy ZA, Ibrahim FA, Abdelgayed SS, Abdel-Rahman RF (2025) Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD\/DEN\/TAA in a rat model: regulation of AMPK\/HIF-1\u03b1\/YAP-1\/TAZ signaling pathways. Naunyn-Schmiedeberg's Arch Pharmacol 398:16131\u201316148","DOI":"10.1007\/s00210-025-04098-8"},{"key":"5573_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104715","volume":"123","author":"H Ghufran","year":"2021","unstructured":"Ghufran H, Azam M, Mehmood A, Butt H, Riazuddin S (2021) Standardization of diethylnitrosamine-induced hepatocellular carcinoma rat model with time based molecular assessment. Exp Mol Pathol 123:104715. https:\/\/doi.org\/10.1016\/j.yexmp.2021.104715","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"5573_CR28","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/cancers15061680","volume":"15","author":"DM Girardi","year":"2023","unstructured":"Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL (2023) Systemic therapy for advanced hepatocellular carcinoma: current stand and perspectives. Cancers 15(6):1680. https:\/\/doi.org\/10.3390\/cancers15061680","journal-title":"Cancers"},{"issue":"19","key":"5573_CR29","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.ccr-14-2018","volume":"21","author":"C Gro\u00df","year":"2015","unstructured":"Gro\u00df C, Steiger K, Sayyed S, Heid I, Feuchtinger A, Walch A, He\u00df J, Unger K, Zitzelsberger H, Settles M, Schlitter AM, Dworniczak J, Altomonte J, Ebert O, Schwaiger M, Rummeny E, Steing\u00f6tter A, Esposito I, Braren R (2015) Model matters: differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib. Clin Cancer Res 21(19):4440\u20134450. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5573_CR30","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/leu.2010.118","volume":"24","author":"RA Hamoudi","year":"2010","unstructured":"Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, Chott A, Raderer M, Gong L, Wlodarska I, De Wolf-Peeters C, MacLennan KA, De Leval L, Isaacson PG, Du M-Q (2010) Differential expression of NF-\u03baB target genes in MALT lymphoma with and without chromosome translocation: Insights into molecular mechanism. Leukemia 24(8):1487\u20131497. https:\/\/doi.org\/10.1038\/leu.2010.118","journal-title":"Leukemia"},{"key":"5573_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111102","volume":"134","author":"AA Hamza","year":"2021","unstructured":"Hamza AA, Heeba GH, Hamza S, Abdalla A, Amin A (2021) Standardized extract of ginger ameliorates liver cancer by reducing proliferation and inducing apoptosis through inhibition oxidative stress\/inflammation pathway. Biomed Pharmacother 134:111102","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5573_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1124\/molpharm.120.000223","volume":"100","author":"R Harati","year":"2021","unstructured":"Harati R, Vandamme M, Blanchet B, Bardin C, Praz F, Hamoudi RA, Desbois-Mouthon C (2021) Drug-drug interaction between metformin and sorafenib alters antitumor effect in hepatocellular carcinoma cells. Mol Pharmacol 100(1):32\u201345. https:\/\/doi.org\/10.1124\/molpharm.120.000223","journal-title":"Mol Pharmacol"},{"key":"5573_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110851","volume":"132","author":"S He","year":"2020","unstructured":"He S, Tang S (2020) WNT\/\u03b2-catenin signaling in the development of liver cancers. Biomed Pharmacother 132:110851. https:\/\/doi.org\/10.1016\/j.biopha.2020.110851","journal-title":"Biomed Pharmacother"},{"key":"5573_CR34","unstructured":"Hosseinzadeh H, Shakib SS, Sameni AK, Taghiabadi E (2013) Acute and subacute toxicity of safranal, a constituent of saffron, in mice and rats. Iran J Pharm Res 12:93"},{"key":"5573_CR35","doi-asserted-by":"publisher","unstructured":"Hu X, Du S, Yu J, Yang X, Yang C, Zhou D, Wang Q, Qin S, Yan X, He L, Han D, Wan C (2016) Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better \u201chousekeeper.\u201d Oncotarget 7(41):66679\u201366688. https:\/\/doi.org\/10.18632\/oncotarget.11439","DOI":"10.18632\/oncotarget.11439"},{"issue":"12","key":"5573_CR36","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1111\/liv.15432","volume":"42","author":"A Jaffe","year":"2022","unstructured":"Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M (2022) Holistic management of hepatocellular carcinoma: the hepatologist\u2019s comprehensive playbook. Liver Int 42(12):2607\u20132619. https:\/\/doi.org\/10.1111\/liv.15432","journal-title":"Liver Int"},{"key":"5573_CR37","doi-asserted-by":"publisher","unstructured":"Jilkova ZM, Kuyucu AZ, Kurma K, Ahmad Pour ST, Roth GS, Abbadessa G, Yu Y, Schwartz B, Sturm N, Marche PN, Hainaut P, Decaens T (2018) Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. Oncotarget 9(13):11145\u201311158. https:\/\/doi.org\/10.18632\/oncotarget.24298","DOI":"10.18632\/oncotarget.24298"},{"key":"5573_CR38","doi-asserted-by":"publisher","unstructured":"Johnson PJ, Kalyuzhnyy A, Boswell E, Toyoda H (2024) Progression of chronic liver disease to hepatocellular carcinoma: Implications for surveillance and management. BJC Reports 2(1). https:\/\/doi.org\/10.1038\/s44276-024-00050-0","DOI":"10.1038\/s44276-024-00050-0"},{"key":"5573_CR39","doi-asserted-by":"publisher","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14(4). https:\/\/doi.org\/10.1186\/gb-2013-14-4-r36","DOI":"10.1186\/gb-2013-14-4-r36"},{"key":"5573_CR40","doi-asserted-by":"publisher","unstructured":"Kim DY (2024) Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer 24(1):622\u2013670. https:\/\/doi.org\/10.17998\/jlc.2024.03.13","DOI":"10.17998\/jlc.2024.03.13"},{"issue":"3","key":"5573_CR41","first-page":"427","volume":"4","author":"X Li","year":"2005","unstructured":"Li X, Zhou X-P, Guan Y-S, Wang Y-XJ (2005) Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in Sprague-Dawley rats. Hepatobiliary & Pancreatic Diseases International: HBPD INT 4(3):427\u2013432","journal-title":"Hepatobiliary & Pancreatic Diseases International: HBPD INT"},{"issue":"24","key":"5573_CR42","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.can-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Can Res 66(24):11851\u201311858. https:\/\/doi.org\/10.1158\/0008-5472.can-06-1377","journal-title":"Can Res"},{"key":"5573_CR43","doi-asserted-by":"publisher","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1). https:\/\/doi.org\/10.1038\/s41572-020-00240-3","DOI":"10.1038\/s41572-020-00240-3"},{"issue":"10","key":"5573_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599\u2013616. https:\/\/doi.org\/10.1038\/s41571-018-0073-4","journal-title":"Nat Rev Clin Oncol"},{"key":"5573_CR45","doi-asserted-by":"publisher","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, De Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, H\u00e4ussinger D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390. https:\/\/doi.org\/10.1056\/nejmoa0708857","DOI":"10.1056\/nejmoa0708857"},{"key":"5573_CR46","doi-asserted-by":"publisher","unstructured":"Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, Antonio MJ, Camelo F, Li T, Nguyen S, Hoang G, Nguyen K, Udupa S, Sazeides C, Shen Y-A, Elgogary A, Reyes J, Zhao L, Kleensang A, Le A (2019) Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Reports 27(2), 491\u2013501.e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.036","DOI":"10.1016\/j.celrep.2019.03.036"},{"key":"5573_CR47","doi-asserted-by":"publisher","unstructured":"Niu M, Yi M, Li N, Wu K, Wu K (2021) Advances of targeted therapy for hepatocellular carcinoma. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.719896","DOI":"10.3389\/fonc.2021.719896"},{"issue":"2","key":"5573_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/cmh.2023.0070","volume":"29","author":"JH Oh","year":"2023","unstructured":"Oh JH, Jun DW (2023) The latest global burden of liver cancer: a past and present threat. Clin Mol Hepatol 29(2):355\u2013357. https:\/\/doi.org\/10.3350\/cmh.2023.0070","journal-title":"Clin Mol Hepatol"},{"issue":"2\u20133","key":"5573_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.toxlet.2009.09.016","volume":"191","author":"D-H Park","year":"2009","unstructured":"Park D-H, Shin JW, Park S-K, Seo J-N, Li L, Jang J-J, Lee M-J (2009) Diethylnitrosamine (DEN) induces irreversible hepatocellular carcinogenesis through overexpression of G1\/S-phase regulatory proteins in rat. Toxicol Lett 191(2\u20133):321\u2013326. https:\/\/doi.org\/10.1016\/j.toxlet.2009.09.016","journal-title":"Toxicol Lett"},{"issue":"9","key":"5573_CR50","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/s2214-109x(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, De Martel C, Vignat J, Ferlay J, Bray F, Franceschi S (2016) Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4(9):e609\u2013e616. https:\/\/doi.org\/10.1016\/s2214-109x(16)30143-7","journal-title":"Lancet Glob Health"},{"key":"5573_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, De Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP, Soerjomataram I (2022) Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer 161:108\u2013118. https:\/\/doi.org\/10.1016\/j.ejca.2021.11.023","journal-title":"Eur J Cancer"},{"issue":"2","key":"5573_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.20538","volume":"41","author":"E Schiffer","year":"2005","unstructured":"Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis\u2020. Hepatology 41(2):307\u2013314. https:\/\/doi.org\/10.1002\/hep.20538","journal-title":"Hepatology"},{"key":"5573_CR53","doi-asserted-by":"crossref","unstructured":"Scholzen T, Gerdes J (2000) The Ki\u201067 protein: from the known and the unknown. J Cell Physiol 182:311\u2013322","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9"},{"issue":"2","key":"5573_CR54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1871520616666161031143301","volume":"17","author":"L Schwartz","year":"2017","unstructured":"Schwartz L, Supuran C, Alfarouk K (2017) The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem 17(2):164\u2013170. https:\/\/doi.org\/10.2174\/1871520616666161031143301","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"5573_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P (2025) Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol 15(2):102446. https:\/\/doi.org\/10.1016\/j.jceh.2024.102446","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"5573_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbcan.2012.10.002","volume":"1835","author":"A Subramaniam","year":"2013","unstructured":"Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BKH, Hui KM, Sethi G (2013) Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1835(1):46\u201360. https:\/\/doi.org\/10.1016\/j.bbcan.2012.10.002","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"3","key":"5573_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5573_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107876","volume":"227","author":"D Tewari","year":"2021","unstructured":"Tewari D, Bawari S, Sharma S, DeLiberto LK, Bishayee A (2021) Targeting the crosstalk between canonical Wnt\/\u03b2-catenin and inflammatory signaling cascades: a novel strategy for cancer prevention and therapy. Pharmacol Ther 227:107876. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107876","journal-title":"Pharmacol Ther"},{"issue":"1_suppl","key":"5573_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/0023677215570086","volume":"49","author":"R Tolba","year":"2015","unstructured":"Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R (2015) Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab Anim 49(1_suppl):59\u201369. https:\/\/doi.org\/10.1177\/0023677215570086","journal-title":"Lab Anim"},{"issue":"21\u201322","key":"5573_CR60","doi-asserted-by":"publisher","first-page":"1800451","DOI":"10.1002\/pmic.201800451","volume":"19","author":"S Udupa","year":"2019","unstructured":"Udupa S, Nguyen S, Hoang G, Nguyen T, Quinones A, Pham K, Asaka R, Nguyen K, Zhang C, Elgogary A, Jung JG, Xu Q, Fu J, Thomas AG, Tsukamoto T, Hanes J, Slusher BS, Cooper AJL, Le A (2019) Upregulation of the glutaminase II pathway contributes to glutamate production upon glutaminase 1 inhibition in pancreatic cancer. Proteomics 19(21\u201322):1800451. https:\/\/doi.org\/10.1002\/pmic.201800451","journal-title":"Proteomics"},{"key":"5573_CR61","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault J-C, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E (2018) Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238\u2013iv255. https:\/\/doi.org\/10.1093\/annonc\/mdy308","journal-title":"Ann Oncol"},{"issue":"2","key":"5573_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/aps.2014.122","volume":"36","author":"J Wei","year":"2015","unstructured":"Wei J, Meng F, Qu K, Wang Z, Wu Q, Zhang L, Pang Q, Liu C (2015) Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin 36(2):241\u2013251. https:\/\/doi.org\/10.1038\/aps.2014.122","journal-title":"Acta Pharmacol Sin"},{"key":"5573_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788667","author":"X Yan","year":"2022","unstructured":"Yan X, Tian R, Sun J, Zhao Y, Liu B, Su J, Li M, Sun W, Xu X (2022) Sorafenib-induced autophagy promotes glycolysis by upregulating the p62\/HDAC6\/HSP90 axis in hepatocellular carcinoma cells. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.788667","journal-title":"Front Pharmacol"},{"issue":"2","key":"5573_CR64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, Qin W, Fan J, Wang C, Gao Q (2024) Precision treatment in advanced hepatocellular carcinoma. Cancer Cell 42(2):180\u2013197. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.007","journal-title":"Cancer Cell"},{"key":"5573_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104765","volume":"212","author":"EH Yousef","year":"2025","unstructured":"Yousef EH, El Gayar AM, El-Magd NFA (2025) Insights into Sorafenib resistance in hepatocellular carcinoma: mechanisms and therapeutic aspects. Crit Rev Oncol Hematol 212:104765. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104765","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"5573_CR66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/nu8030156","volume":"8","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li H-B (2016) Dietary natural products for prevention and treatment of liver cancer. Nutrients 8(3):156. https:\/\/doi.org\/10.3390\/nu8030156","journal-title":"Nutrients"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05573-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:13:17Z","timestamp":1789978397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05573-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5573"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05573-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}